Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® ...
PTC Therapeutics withdrew a New Drug Application for Translarna, a muscular dystrophy treatment, after the Food and Drug Administration indicated it would likely not grant approval.
With the writing apparently on the wall, PTC Therapeutics has called off its latest bid for FDA approval of its Duchenne muscular dystrophy (DMD) drug Translarna. | Late Thursday, PTC revealed that ...
NMD Pharma A/S, a clinical-stage biotechnology company dedicated to developing novel therapies to restore skeletal muscle health, today announced that top-line data results from its Phase 2a ...
The Muscular Dystrophy Association announces nearly $2 million for collaborative research on neuromuscular conditions. · GlobeNewswire Inc. New York, Dec. 03, 2025 (GLOBE NEWSWIRE) -- The Muscular ...
Tokyo, Feb. 13 (Jiji Press)--An advisory panel to Japan's health minister decided Friday to allow public health insurance coverage for a gene therapy for muscular dystrophy beginning Feb. 20 and set ...
Myostatin, a protein that blocks muscle growth, has shown promising results as a potential therapeutic target for treating muscular dystrophy in animal studies, where its inhibition led to increased ...
A preclinical study led by the Germans Trias i Pujol Research Institute (IGTP), in collaboration with the Institut de ...
New York, Dec. 03, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today announced the awarding of seven new collaborative research grants totaling nearly $2 million to advance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results